Core Viewpoint - PCI Biotech Holding ASA is proposing to dissolve the company and delist its shares from Euronext Oslo Børs due to the absence of operational activity and the expectation that such activity will not resume [2][3]. Group 1: Company Dissolution - The Board of Directors has proposed the resolution to dissolve PCI Biotech as there is no longer any operational activity within the company [2]. - The wholly owned subsidiary, PCI Biotech AS, has also resolved to initiate a parallel dissolution process [2]. Group 2: Delisting from Euronext Oslo Børs - The proposed resolution to delist the shares is based on the lack of operational activity and a limited asset base, leading the Board to conclude that the company is no longer suitable for public trading [3]. - The Board recommends that the delisting should occur as soon as possible [3].

Core Insights - Kraig Biocraft Laboratories, Inc. is recognized for its advancements in spider silk technology, featured on the cover of National Geographic's March 2026 issue [1][13] Group 1: Company Achievements - The article highlights Kraig Labs' innovative approach to producing spider silk fibers using genetically enhanced silkworms, emphasizing its cost-efficiency and high quality [2] - Kraig Labs' recombinant spider silk technology has been tested successfully, demonstrating its strength by towing a car and suspending a person from the ceiling with a single 0.35-ounce loop of thread [4] - The recognition by National Geographic marks a significant milestone for Kraig Labs and the biomaterials innovation sector [3] Group 2: Commercialization and Market Potential - The feature discusses the scalability of silkworm cultivation combined with the performance properties of spider silk, indicating growing commercial opportunities for spider silk biomaterials [2] - Kraig Labs is preparing to ramp up production operations to meet the increasing market demand for high-performance, sustainable fiber and fabric solutions [6]

Company Overview - Generate Biomedicines, a drug developer based in Somerville, Massachusetts, is targeting a valuation of up to $2.17 billion in its upcoming initial public offering (IPO) in the United States [1] - The company is backed by venture firm Flagship Pioneering and aims to raise up to $425 million by offering 25 million shares priced between $15 and $17 each [1] IPO Details - Generate Biomedicines plans to list on the Nasdaq under the symbol "GENB" [1] - The IPO comes as biotech offerings have seen a strong start this year, following a sluggish 2025, attributed to easing interest rates and increased capital inflows into the sector [1] Underwriters - The underwriters for the offering include Goldman Sachs, Morgan Stanley, Piper Sandler, Guggenheim Securities, and Cantor [1]

This forgotten stock might be too risky even for contrarian investors.Inovio Pharmaceuticals (INO +0.58%) isn't a particularly well-known or prominent name in the biotech industry, but some may remember it as one of those smaller companies that sought to develop and market a coronavirus vaccine in the early years of the pandemic. Inovio's efforts were unsuccessful, and since then, the stock has lost significant market value. Will it continue moving in the wrong direction? Or is there a rebound in the cards? ...

HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) ("Zura†or the "Company†), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., ...

Group 1: Supreme Court Ruling and Tariff Implications - The Supreme Court ruled 6-3 to void most tariffs imposed by Trump, stating the emergency law used did not permit such tariffs [1] - Trump announced a new global levy of 10% to 15% that may last five months while seeking more sustainable solutions [1] Group 2: Market Reactions and Corporate Concerns - The stock market reacted positively to the Supreme Court's decision, with all three main indexes showing weekly gains, and the Nasdaq ending a five-week losing streak [4][5] - Corporate America is facing significant uncertainty regarding planning due to fluctuating tariffs and supply chain issues, as highlighted by Arthur Laffer Jr. [2] Group 3: Sector Performance and Earnings Outlook - High stock valuations and fears of AI disruption have pressured technology and other sectors, with the S&P 500 software and services index down over 20% this year [7][10] - Major software firms' earnings, including Salesforce and Intuit, are anticipated this week, as investors seek insights into the impact of AI spending [7][10] Group 4: Individual Stock Movements - Eli Lilly's stock rose 4% following positive trial results against a competitor's obesity drug [8][10] - Cryptocurrency-related stocks fell as Bitcoin dropped approximately 2%, affecting companies like Coinbase Global [8][10] - Gold and silver miners saw gains, with Newmont and Hecla Mining increasing by 1.1% and 2.5% respectively [8][10]

Company Overview - Apogee Therapeutics is a biotechnology company focused on developing extended half-life monoclonal antibodies for treating atopic dermatitis and chronic obstructive pulmonary disease (COPD) [6][7] - The company aims to address significant unmet needs in the healthcare market, particularly in dermatology and respiratory diseases [6][7] - As of February 17, 2026, the company's market capitalization is $3.82 billion, with a share price of $69.64, reflecting a one-year price change of 99.37% [4][6] Recent Developments - On February 17, 2026, Perceptive Advisors disclosed the purchase of 978,662 shares of Apogee Therapeutics, valued at approximately $61.64 million [1][2] - Following this transaction, Perceptive Advisors holds a total of 2,330,651 shares, with the value of their position increasing by $122.20 million due to new purchases and share price appreciation [2] - This acquisition represents 3.14% of Perceptive Advisors' 13F assets under management (AUM) as of December 31, 2025 [6] Financial Performance - Apogee Therapeutics reported a net income of -$253.67 million over the trailing twelve months (TTM) [4] - The company is expected to generate revenue from product sales upon regulatory approval of its therapies [7] - Long-term investors are encouraged to focus on the differentiation of the pipeline in atopic dermatitis and COPD, as well as the company's capital discipline [12]

Core Insights - Celcuity is focused on developing targeted cancer therapies and diagnostic platforms, particularly in precision medicine for oncology [1][6] - Perceptive Advisors increased its stake in Celcuity by 203,881 shares, valued at approximately $16.76 million, reflecting confidence in the company's growth potential [2][7] - Celcuity's share price surged 700% over the past year, indicating strong market performance and investor interest [7][11] Company Overview - As of February 17, 2026, Celcuity's stock price was $107.32, with a market capitalization of $4.97 billion and a net income of -$162.72 million [4] - The company operates a clinical-stage biotechnology model, focusing on proprietary drug candidates and diagnostic technologies, with future revenue expected from licensing and partnerships [8] Product Development - Celcuity's lead drug candidate, Gedatolisib, has received FDA acceptance for a New Drug Application with a PDUFA goal date of July 17, 2026, based on Phase 3 trial data [9][10] - Gedatolisib has been granted Breakthrough Therapy and Fast Track designations, indicating its potential significance in treating advanced breast cancer [9] Investment Implications - Perceptive Advisors' stake in Celcuity represents 5.62% of its reported assets under management (AUM), suggesting a strong conviction in the company's future [7][11] - The upcoming regulatory decision on Gedatolisib is critical for long-term investors, as it will determine the drug's market entry and potential revenue generation [11]

Company Overview - Arcellx is a clinical-stage biotechnology company focused on proprietary cell therapy platforms to address unmet medical needs in oncology [5] - The company has a specialized pipeline targeting multiple myeloma and hematologic malignancies, positioning itself at the forefront of next-generation immunotherapies [5] - As of February 17, 2026, Arcellx's market capitalization is $4.06 billion, with a revenue of $35.90 million and a net income of -$217.90 million [4] Recent Developments - Perceptive Advisors disclosed a sale of 1,002,282 shares of Arcellx, valued at approximately $79.96 million, during the fourth quarter of 2026 [2][1] - The quarter-end value of Arcellx's position declined by $107.06 million, reflecting both the share reduction and share price movements [2] - Arcellx shares were priced at $70.20, representing a 9.2% increase over the past year, but underperforming the S&P 500 by 4.3 percentage points [7] Pipeline and Product Focus - Arcellx develops immunotherapies, primarily focusing on CART-ddBCMA for relapsed or refractory multiple myeloma, with additional candidates targeting acute myeloid leukemia, myelodysplastic syndrome, and solid tumors [8] - The company's anito-cel is in Phase 3 trials for relapsed or refractory multiple myeloma in partnership with Gilead's Kite unit, indicating a more advanced position compared to early proof-of-concept data [10] Market Position and Competition - The recent share sale by Perceptive Advisors indicates a strategic move as Arcellx faces competition not only from other approved CAR-T therapies but also from new delivery models [6] - The volatility in Arcellx's stock price highlights the rapid shifts in sentiment within the biotechnology sector, particularly following data releases and market reactions [9][10] - Analysts from Guggenheim and Citi suggested that the sell-off following a three-patient data set was overdone, indicating potential for recovery [9]

Krystal Biotech develops redosable gene therapies targeting rare skin diseases, with a late-stage clinical pipeline and expanding portfolio.Redmile Group reported a purchase of 16,317 shares of Krystal Biotech (KRYS 0.33%) in its February 17, 2026, SEC filing, with the estimated transaction value at $3.43 million based on quarterly average pricing.What happenedAccording to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Redmile Group increased its position in Krystal Biotech by 16 ...